NASDAQ · Healthcare · Biotechnology
Lyell Immunopharma, Inc.
LYEL
Lyell Immunopharma, Inc. CEO Lynn Seely · Market cap $339.3M.
$13.80
+0.22 · +1.62%
52w hi $45.0052w lo $7.20
Off 52w high 66.7%
88
STRONG
Current InsiderScore
Corp · 90d
2
2 buys · 0 sales
Cong · 90d
0
0 buys · 0 sales
Signals ≥ 60 · 12mo
4
4 strong · 0 notable
Analyst consensus
Strong Buy
Avg PT $39.50
Section 01
Recent Form 4 filings
4 filings on file
| Date | Insider | Role | Action | Shares | Price | Value | Score |
|---|---|---|---|---|---|---|---|
| Nov 04 | ARCH Venture Fund XIII, L.P. | Buy | 2,321,262 | $10.77 | +$25.00M | 88 | |
| Nov 04 | ARCH Venture Partners IX, LLC | Buy | 2,321,262 | $10.77 | +$25.00M | 88 | |
| Mar 06 | ARCH Venture Partners IX, LLC | Buy | 488,090 | $25.61 | +$12.50M | 86 | |
| Mar 06 | ARCH Venture Fund XIII, L.P. | Buy | 488,090 | $25.61 | +$12.50M | 86 |
Section 02
Recent STOCK Act disclosures
No disclosures yet
No STOCK Act disclosures on record for this ticker.
Section 03
InsiderScore history
Rolling 12 months · peak score per month
DecJanFebMarAprMayJunJulAugSepOctNov